Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
Ontology highlight
ABSTRACT: The U.S. Food and Drug Administration (FDA) allows patients with serious illnesses to access investigational drugs for "compassionate use" outside of clinical trials through expanded access (EA) Programs. The federal Right-to-Try Act created an additional pathway for non-trial access to experimental drugs without institutional review board or FDA approval. This removal of oversight amplifies the responsibility of physicians, but little is known about the role of practicing physicians in non-trial access to investigational drugs. We undertook semi-structured interviews to capture the experiences and opinions of 21 oncologists all with previous EA experience at a major cancer center. We found five main themes. Participants with greater EA experience reported less difficulty accessing drugs t
SUBMITTER: Stout J
PROVIDER: S-EPMC8682887 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA